ITCC-P4, a non-profit initiative, is passionately committed to a future free from childhood cancer. It provides the world’s most extensive collection of freshly patient-derived pediatric tumor models, enriched with comprehensive molecular and pharmacological data. This empowers advanced preclinical cancer research, crucial for meeting FDA guidelines in the approval of novel pediatric oncology drugs. https://itccp4.com/

By blending EPO’s scientific expertise with the knowledge of ITCC-P4’s globally recognized academic disease-experts, we strive to deliver excellent services to elevate your drug programs.

We are also delighted to announce steady progress in our pediatric research initiatives, with two new publications offering insights into pediatric cancer mechanisms and drug responses.

In a collaborative approach we have demonstrated that elimusertib shows potent preclinical antitumor activity in pediatric solid tumor models, potentially leading to significant clinical responses in patients. https://pubmed.ncbi.nlm.nih.gov/36753540/

Another publication highlights the RAS pathway as a promising therapeutic target for alveolar rhabdomyosarcoma (aRMS), a group of pediatric cancers with skeletal muscle characteristics. https://pubmed.ncbi.nlm.nih.gov/38159110/

We’re excited to harness our scientific expertise alongside leading pediatricians to elevate your drug programs. Please reach out directly to our subject matter expert Turn on Javascript!?subject=Newsletter%20Epo%20GmbH" title="Email-Dr. Dennis Gürgen">Dr. Dennis Gürgen for any queries or to discuss your project.

Best regards,

Jens Hoffmann & Wolfgang Walther

CEO & CSO at EPO Berlin-Buch